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iultiple achievements were obtained in the field of athero-
hrombosis in 2003 to 2004, from basic and experimental
esearch to major clinical trials, setting up new standards,
articularly in the understanding and treatment of coronary
rtery disease. The review is divided into four sections
overing basic and experimental research, clinical imaging,
erum markers for high-risk stratification, and emergent
herapies for coronary and systemic atherothrombosis. Final
election of the cited articles was performed on the basis of
linical relevance and scientific merit.
ASIC AND EXPERIMENTAL
icrovessels, plaque hemorrhage, and plaque destabili-
ation. Our understanding of high-risk atherosclerosis is
ow evolving from the traditional theory of passive lipid
eposition to a more complex multifactorial theory of a
echanism involving the adventitial vasa-vasorum and the
unica media. Kolodgie et al. (1) tested the hypothesis that
ntraplaque hemorrhage may be a significant contributor to
ipid-core expansion through the accumulation of free
holesterol from extravasated erythrocyte membranes. Cor-
nary lesions were stained for markers of previous in-
raplaque hemorrhage. Coronary fibroatheromas with cores
n a late stage of necrosis or thin caps had increased iron
eposits, glycophorin A, and greater macrophage infiltra-
ion, as shown in Figure 1.
These results suggest that accumulation of erythrocyte
embranes within atherosclerotic plaques contributes to
ipid core expansion as well as to macrophage infiltration,
hus increasing the risk of plaque destabilization (1).
A step forward exploring the mechanistic relationship
etween intraplaque hemorrhage and high-risk atheroscle-
osis was elegantly described by Kockx et al. (2) who
dentified intraplaque hemorrhage from microvessels trig-
ering macrophage activation and foam cell formation in
arotid lesions, as shown in Figure 2. The investigators
oncluded that focal intraplaque microhemorrhage from
eaking microvessels initiate platelet and erythrocyte depo-
ition, leading to iron deposition, macrophage activation,
nd foam cell formation (2). More recently, Moreno et al.
3) identified microvessels as an independent predictor of
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ccepted June 23, 2004.laque rupture. Again, all these features may lead to plaque
estabilization, precipitating acute ischemic events.
ink between inflammation and thrombogenicity. The
ink between inflammation and thrombogenicity was
tudied by Hutter et al. (4) by evaluating apoptosis and
issue factor (TF) expression in macrophages within
uman carotid and coronary lipid-rich plaques.
aspase-3 messenger ribonucleic acid, a marker of apo-
tosis and TF, was higher in lipid-rich compared with
brous plaque components (p  0.01) and correlated
ith high macrophage content (p  0.05), as shown in
igure 3. Furthermore, induction and colocalization of
F and active caspase-3 were found in monocytes cul-
ured in the presence of oxidized low-density lipoprotein
LDL) (p  0.05). Both antigens were significantly
ecreased after co-treatment with a caspase inhibitor (p
0.05) and were absent in untreated control cells.
The study shows that expression of TF closely related to
poptotic macrophages in lipid-rich plaques, highlighting
he possible mechanistic impact of high lipid content in
acrophage apoptosis and plaque thrombogenicity (4).
The TF expression is also increased by activated platelets
ttached to monocytes. The effect of abciximab (non-
elective glycoprotein IIb/IIIa-receptor antagonist) on
onocyte TF expression was evaluated in whole blood in
itro by Steiner et al. (5). After thrombin receptor stimula-
ion, abciximab (50 g/ml) reduced the mass of platelets
ttached to monocytes with reduced expression of monocyte
F antigen, chromogenic TF activity, and TF messenger
ibonucleic acid. The investigators concluded that abcix-
mab suppresses monocyte TF through a reduction of
onocyte-platelet cross-talk. This finding may explain the
rotective effect of abciximab on the microcirculation after
cute coronary syndromes (5).
In experimental animal research, Danenberg et al. (6)
valuated direct proinflammatory and prothrombotic effects
f complement reactive protein (CRP) on monocytes and
ndothelial cells in vivo by subjecting wild-type mice, which
o not express CRP, and human CRP-transgenic (CRPtg)
ice to two models of arterial injury (6). Baseline serum
RP levels were undetectable in wild-type mice and 18 6
g/l in CRPtg mice. Transluminal wire injury led to
omplete thrombotic occlusion of the femoral artery at 28
ays in 17% of wild-type mice compared with 75% of
RPtg arteries (p  0.05), as seen in Figure 4. The
nvestigators concluded that arterial injury in CRPtg mice
esults in a higher rate of thrombotic occlusion, suggesting
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Year in Atherothrombosis December 7, 2004:2099–110n inflammatory-thrombotic axis with a prothrombotic
ction of CRP.
olecular imaging of inflammation, microvessels, and
hrombus. Conventional imaging relies on anatomic, phys-
ologic, or metabolic heterogeneity to provide image con-
rast. Molecular imaging is based on a signal imaging
lement attached to a carrier that transports a ligand that
ecognizes the target molecule or process to image (7). A
umber of disease entities have molecular or cellular pro-
esses that can be investigated with this methodology.
xamples of signal imaging elements based on magnetic
esonance imaging (MRI) include ultrasmall superparamag-
etic iron oxide nanoparticles (USPIO) or gadolinium
helates; examples of carriers include liposomes, lipid-
ncapsulated nanoparticles, and others; examples of ligands
re small peptides, monoclonal antibodies, peptidomimet-
cs, and so on; examples of target molecules, cells, or
rocesses to image that may indicate a high-risk for athero-
clerosis include macrophages, macrophage apoptosis,
hrombus formation, angiogenesis, and activated endothe-
ial integrins (7–12).
In vivo detection of macrophages using USPIO in human
laques by MRI was performed on 11 symptomatic patients
cheduled for carotid endarterectomy. Histologic and electron
icroscopy analyses of the plaques showed USPIO in plaque
acrophages in 10 of 11 patients. Histologic analysis showed
SPIO in 27 of 36 (75%) of the ruptured and rupture-prone
esions and 1 of 14 (7%) of the stable lesions. These results
uggest that USPIO-guided macrophage identification with
igure 1. (A) Low power view of a thin cap fibroatheroma with large n
acrophages (B) (200). (C) Shows intense staining for glycophorin A in
100). (D) Shows iron deposits (blue pigment) in a macrophage-rich
erivascular deposits of von Willebrand factor in microvessels, indicating t
rom Kolodgie FD, Gold HK, Burke AP, et al. N Engl J Med 2003;349:
igure 2. Microvessels (mv) with intracellular von Willebrand factor (vWf)
n flat endothelial cells (A). Microvessels with perivascular macrophages
nd increased endothelial vWf expression and perivascular vWf depositiona
B). Reproduced with permission from Kockx MM, Cromheeke KM,
naapen MW, et al. Arterioscler Thromb Vasc Biol 2003;23:440–6.RI may offer noninvasive risk stratification of atherosclerotic
laques at the cellular level in vivo (8).
Identification of macrophage apoptosis, a major process
n plaque rupture and thrombus formation, was performed
sing human recombinant annexin V labeled with
echnetium-99m in five hypercholesterolemic rabbits and
ompared with five controls. Intense uptake of radiolabel
as observed in the experimental group, mostly at areas
eavily infiltrated by macrophages with deoxyribonucleic
cid fragmentation and apoptotic nuclei (9), suggesting that
echnetium-99 radiolabeled annexin V can identify molec-
lar changes in macrophages undergoing apoptosis.
Thrombus imaging using molecular MRI continues to
volve as a potentially useful tool to detect complicated
laques responsible for acute or subacute thrombosis. Using
novel fibrin-binding, gadolinium-labeled peptide, EP-
873, MRI successfully identified 25 thrombi in the Rus-
ell’s viper venom hypercholesterolemic rabbit model. These
esults confirm in vivo feasibility of molecular MRI for the
etection of acute and subacute thrombosis in experimental
therosclerosis (10).
Another major step forward in molecular imaging was the
uccessful imaging of angiogenesis in early atherosclerosis.
sing v3 integrin-targeted, paramagnetic nanoparticles
njected intravenously, angiogenesis was detected as a 47%
nhancement in the MRI signal within the atherosclerotic
all of the abdominal aorta in hypercholesterolemic rabbits,
s seen in Figure 5 (11). This molecular imaging approach
ight help to study the evolution of atherosclerosis in
usceptible individuals as well as for determining the re-
ponsiveness of individual patients to antiatherosclerotic
herapies.
Invasive atherosclerotic molecular imaging with intravas-
ular ultrasound also advanced significantly. Activated en-
othelial integrins including intercellular adhesion
olecule-1, vascular cell adhesion molecule-1, fibrinogen,
brin, and TF were imaged with targeted echogenic immu-
oliposome (ELIP) using intravascular ultrasound. Detec-
ion of coronary activated endothelium was successfully
erformed in hypercholesterolemic Yucatan mini-swine af-
er ELIP injection by enhanced echogenicity using three-
imensional image reconstruction and videodensitometric
c core (Movat pentachrome, 20), heavily infiltrated by CD68-positive
ocyte membranes within the necrotic core, together with cholesterol clefts
n deep within the plaque (Mallory’s stain, 200). (E) Shows diffuse,
aky vessels border the necrotic core (400). Reproduced with permission
–25.ecroti
erythr
regio
hat lenalysis (12).
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December 7, 2004:2099–110 Year in Atherothrombosisetabolic syndrome and peroxisomal proliferator-
ctivated receptors (PPAR). Two major areas of research
ummarize recent advances in the metabolic syndrome and
therothrombosis. The first one is a consequence of the
igure 3. Active caspase-3 (A), tissue factor (B), and CD-68 immunostain
LIP) in serial sections of a human coronary atheroma. FIB  fibrotic.
irculation 2004;109:2001–8.
igure 4. (A) Complete arterial occlusion at 28 days after femoral wire
njury in complement reactive protein-transgenic (CRPtg) (n  8) and
ild-type mice (n  12). (B to E) Photomicrographs of wild-type (left)
nd CRPtg (right) femoral arteries stained by Verhoeff elastin stain (B and
) and -actin (D and E). Note the reduced smooth muscle cells content
n the intraluminal lesion of the CRPtg mouse. Reproduced with permis-p
ion from Danenberg HD, Szalai AJ, Swaminathan RV, et al. Circulation
003;108:512–5.iscovery of leptin (13), which lead to the elucidation of the
ole of cannabinoid receptor type 1 (CB1) in food intake.
ota et al. (14) showed that the lack of CB1 gene in mice
auses hypophagia and leanness. Hypothalamic CB1 mes-
enger ribonucleic acid was found to be co-expressed with
europeptides known to modulate food intake, such as
orticotropin-releasing hormone, cocaine-amphetamine-
egulated transcript, melanin-concentrating hormone, and
repro-orexin, indicating a possible role for endocannabi-
oid receptors within central networks governing appetite.
hese results indicate that the cannabinoid system is an
ssential endogenous regulator of energy homeostasis via
entral orexigenic as well as peripheral lipogenic mecha-
isms and, therefore, might represent a very promising
arget with which to treat diseases like the metabolic
yndrome.
The second area of research is related to PPARs, a group
f ligand-activated transcription factors belonging to the
uclear receptor superfamily, which also includes the steroid
nd thyroid hormone. Three subfamilies have been de-
cribed with different tissue distribution and effects:
PAR-, PPAR-, and PPAR-.
The PPAR- is activated by polyunsaturated fatty acids,
xidized derivatives, and fibrates, including fenofibrate or
emfibrozil. The PPAR- controls expression of genes
mplicated in lipid metabolism. The PPAR- is expressed
n endothelial cells, smooth muscle-cells, monocyte/
acrophages, and T cells. Specific roles of PPAR- in
ndothelial cells include interference with leukocyte
ytokine-induced expression of adhesion molecules
VCAM-1) through inhibition of the master transcriptional
uclear factor-kappa-B in the VCAM-1 promoter (15),
nhancing endothelial nitric oxide (NO) synthase expres-
ion and release (16), and reducing foam cell and fatty streak
ormation through the high-density lipoprotein (HDL)
Apo) A-I–mediated cholesterol efflux (17). Moreover,
PAR- ligands downregulate the expression of the
poB48-remnant receptor in differentiated macrophages
nd reduce the uptake of glycated LDL and triglyceride-rich
emnant lipoproteins (18); PPAR- also regulates macro-
) show brown labeling of cells (arrows) along the border of the lipid-core
duced with permission from Hutter R, Valdiviezo C, Sauter BV, et al.ing (C
Reprohage intracellular cholesterol metabolism and decreases the
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Year in Atherothrombosis December 7, 2004:2099–110atio of intracellular cholesteryl ester to free cholesterol by
educing acyl-coenzyme A:cholesterol acyltransferase-1 ac-
ivity (19). As a result, PPAR- is a major regulator in
rucial steps of atherosclerosis.
The PPAR-, in contrast, is a key regulator of glucose
omeostasis and adipogenesis. Ligands of PPAR- include
aturally occurring fatty acids and prostaglandin derivatives,
nd glitazones, insulin-sensitizing drugs presently used to
reat patients with type 2 diabetes. The PPAR- is also
xpressed in endothelial cells, smooth muscle-cells, macro-
hages, and T cells. The PPAR- activators increase
ndothelial production of NO and decrease endothelial
ecruitment of activated T cells (20). A major effect of
PAR- in atherosclerosis is related to antiangiogenic
ffects, inhibiting vascular endothelial growth factor expres-
ion and reducing endothelial tube formation (21). The
ffects of PPAR- activators on smooth muscle cells are
elated to inhibitory effects on migration, with decreased
xpression of matrix-degrading enzymes (15). These effects
re also seen in macrophages reducing the expression of
atrix metalloproteinase (MMP)-9, and osteopontin, and
nhancing the release of the anti-inflammatory cytokine
nterleukin-1 receptor antagonist, suggesting a broad anti-
nflammatory effect of PPAR- in these cells (22). Of note,
PAR- activators may also reduce the lipid content of
laques by enhancing reverse cholesterol transport and by
pregulating the genes responsible for scavenger-receptor
lass B type I human homologue, for adenosine
riphosphate-binding cassette transporter-1 and for apoli-
oprotein A1, thereby facilitating efflux of free cholesterol
rom the plaque and its transport to the liver. To investigate
igure 5. Percent enhancement of adventitial signal (false-colored from blu
C) 2 h after v3-targeted nanoparticles in cholesterol-fed rabbits.
v3-integrin staining in adventitial neovessels (black arrowheads) (D).
dhesion molecule (F) in aorta from cholesterol-fed animal in (A) at 60
ECAM expression at interface between media (M) and adventitia (Av).
t al. Circulation 2003;108:2270–4.his mechanism, Corti et al. (23) documented plaque eegression using MRI in atherosclerotic rabbits exposed to a
ew selective PPAR--activator (23). The combination of
tatin with PPAR--activator was superior to either medi-
ation alone, with decreased macrophage content and
MP activity and increased smooth muscle cell/collagen
ontent in atherosclerotic lesions.
Positive results with PPAR- agonists in humans are
ow emerging. Treatment of patients with type 2 diabetes
ith glitazones significantly reduced CRP levels as well as
hite blood cell count and MMP-9 serum levels (24). In
ddition, a randomized trial in patients with coronary artery
isease and type 2 diabetes mellitus demonstrated a signif-
cant reduction of serum amyloid A after two weeks of
osiglitazone treatment and a significant decrease in tumor
ecrosis factor- levels after six weeks (25). In addition,
litazone treatment decreased sCD40L levels as well as
erum levels of MMP-9 two weeks after the initiation of
reatment (26). Considering the popularity of PPAR-
gonists in clinical practice, these medications hold promise
o reduce atherosclerosis in patients with or without diabe-
es mellitus.
Finally, PPAR- is a key regulator of inflammation and
ctivation of macrophages and will play a pivotal role in
therosclerosis, but more studies are needed (27).
enomics in atherothrombosis. Many gene variants have
een investigated for their effects on coronary artery disease
nd myocardial infarction (MI) risks. Polymorphisms in
enes encoding ApoE, Lp(a) or Apo(a), ApoAI, Apo-
III, ApoIV, t-PA, fibrinogen, plasminogen activator
nhibitor, von Willebrand factor, platelet glycoprotein IIIa,
ipoprotein lipase, cholesterol ester hydrolase, cholesterol
ed) from aortic segments at renal artery (A), mid-aorta (B), and diaphragm
nohistochemistry of v3-integrin showing thickened intima (I) and
nostaining of neovascular v3-integrin (E) and platelet endothelial cell
olid arrows delineate v3-integrin expression, and open arrows mark
duced with permission from Winter PM, Morawski AM, Caruthers SD,e to r
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December 7, 2004:2099–110 Year in Atherothrombosisonverting enzyme, angiotensinogen, endothelial nitric ox-
de synthase, connexin 37, MMP-3, and other proteins have
een associated in certain populations with a high risk of
therosclerosis, coronary artery disease, and MI (28).
ithin the field of single-nucleotide polymorphisms
SNP), previous studies have shown three members of the
hrombospondin (TSP) family (TSP-1, -2, and -4) to be
ssociated with MI (29). The results of these studies are very
romising, but require independent replication and proof of
ause-effect.
One of the most impressive advances in the genomics of
therothrombosis in 2004 was the simultaneous work by
wo independent groups implicating leukotriene coding
enes and heart disease. The first study from The deCODE
enetics group in Iceland identified the first common gene
ssociated with MI and stroke (30,31). The gene codes for
protein known as FLAP, or 5-lipoxygenase-activating
rotein, required for the synthesis of leukotrienes. By sifting
hrough the genomes of 700 MI patients and their unaf-
ected relatives, a broad band of deoxyribonucleic acid on
hromosome 13 (13q12-13) was identified. A four-marker
NP haplotype in this locus was present in 30% of MI
atients, stimulating neutrophils to produce more leukotri-
ne B4, and nearly doubling the risk of heart attacks and
troke (30). Indeed, based on its discovery, the deCODE
eam is gearing up for a 200-person clinical trial in Iceland
f an experimental inhibitor of FLAP, testing levels of
ertain molecular markers for cardiovascular disease (31).
he second study, a collaborative effort from investigators at
niversity of Southern California and University of
alifornia in Los Angeles, identified variant 5-lipoxygenase
enotypes predisposing to early atherosclerosis. Carriers of
wo variant alleles developed increased intima-media carotid
hickness similar to that observed in diabetic patients. In
ddition, plasma level of CRP was doubled. Of note, dietary
rachidonic acid significantly enhanced the atherogenic
ffect of the genotype, whereas dietary intake of n-3 fatty
cids blunted the effect (32).
In another study, Wang et al. (28) performed the first
arge-scale genomewide search for susceptibility genes for
I in a well-characterized U.S. cohort consisting of 1,613
ndividuals in 428 multiplex families with familial prema-
ure coronary artery disease and MI. Genotyping was
erformed at the National Heart, Lung, and Blood Institute
ammalian Genotyping Facility through the use of 408
arkers that span the entire human genome every 10 cM.
sing linkage analysis with multiple genome-wide scans,
ne novel significant susceptibility locus was detected for
I on chromosomal region 1p34-36, with a multipoint
llele-sharing p value of 1012 (LOD  11.68) (28),
ntroducing the utility of massive genotyping in the field of
enomic atherothrombosis. These and others advances in
he genomics of MI (33,34) provide a framework for the
ltimate cloning of a gene in the fight against atherothrom-
osis and ischemic heart disease.LINICAL IMAGING OF ATHEROSCLEROSIS
eliable, noninvasive imaging modalities able to detect
therothrombotic disease in the various stages and regions
nd to characterize the composition of the plaques are
linically desirable. Most of the invasive techniques, such as
oronary angiography and intravascular ultrasound, identify
uminal diameter or stenosis, wall thickness, and plaque
olume. However, two emerging and most promising tech-
iques—computed tomography and magnetic resonance—
re likely to be facilitated and used by wider medical
ommunities and applied to larger populations because
hese techniques are noninvasive and can evaluate calcifica-
ion and luminal stenosis (computed tomography) and
haracterize plaque composition (magnetic resonance) (35).
ithin the last year, both technologies achieved significant
rogress. Furthermore, plaque imaging with invasive meth-
ds continues to be moving forward.
omputerized tomography and calcium scoring in pri-
ary prevention. Today, two different modes of computed
omography are available (35). One employs non-
echanical movement of the X-ray source (i.e., electron
eam computed tomography), and another involves the
otion of the X-ray source and table, combined with
ultiple detectors to acquire the data in spiral or helical
ashion (i.e., multidetector-row computed tomography).
lthough electron-beam computed tomography has been
onsidered the gold standard for the assessment of calcified
laques, multidetector-row computed tomography usually
ncludes an initial non-enhanced scan for the screening and
uantification of coronary artery calcium followed by com-
uter tomography angiography for direct visualization of
oronary artery disease.
Cardiovascular prevention in asymptomatic individuals
ontinues to be a changing target, even after the aggressive
hanges recently published by the Third Adult Treatment
anel of the National Cholesterol Education Program (36).
s a matter of fact, these guidelines may require revision to
mprove risk stratification in addition to the Framingham
isk score (FRS), as shown in Table 1 (37).
Greenland et al. (38) evaluated the additional benefit of
sing both coronary artery calcium scores plus the FRS in
,461 asymptomatic, middle-aged (45 years) adults with
t least one coronary risk factor followed for 8.5 years after
he computed tomography scan. Compared with a coronary
rtery calcium score of zero, a score300 predicted MI and
oronary death (hazard ratio, 3.9; 95% confidence interval
CI], 2.1 to 7.3; p  0.001). Most importantly, coronary
rtery calcium scores were predictive of risk among patients
ith an FRS higher than 10% (p  0.001) but not with an
RS lower than 10%, supporting the hypothesis that high
oronary artery calcium scores can modify the predicted risk
btained from FRS alone, especially among patients in the
ntermediate-risk category in whom clinical decision-
aking is most uncertain (38).
Within the same prognostic context of calcium scores,
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Year in Atherothrombosis December 7, 2004:2099–110aggi et al. (39) conducted an observational study relating
he occurrence of acute MI to coronary artery calcium
rogression in 817 asymptomatic subjects referred for se-
uential electron-beam tomographic imaging (average in-
erval 2.2 years). Coronary artery calcium volume score
rogression was greater in patients with MI when compared
ith asymptomatic subjects without MI. In addition, cor-
nary artery calcium scores were higher in patients with
iabetes mellitus, although patients with score 0 demon-
trated excellent survival rate independent of diabetes status
98.8% for diabetics and 99.4% for non-diabetics; p  NS)
40). Finally, for clinical practice, a small study suggested
hat a coronary artery calcium score 400 may justify
uclear stress testing (41) because the prevalence of obstruc-
Table 1. Pretest Probability of a Coronary Eve
Coronary Risk Factors*
Pretest Probability
of a Coronary
Event Within 10 Years
Probability Within 10
Results of Elect
Calcium Score >80
1.0 3.0
2.0 6.5
3.0 9.5
4.0 12.5
5.0 15.0
6.0 18.0
7.0 20.0
10.0 27.0
15.0 38.0
20.0 46.0
Other probabilities of coronary event were calculated on the
or exercise electrocardiography. Please note that a 10% prob
to 2.2% if the score is 80. Reproduced with permission fro
igure 6. Comparison between X-ray angiography (upper row, A) and po
n the same patient. Three-dimensional volume-rendering postprocessed C
B  diagonal branch; Cx  circumflex; LAD  left anterior descending
rtery; RCA  right coronary artery; RVD  right ventricular diagonal; V  v
ecker C. Circulation 2002;106:2026–34.ive coronary artery disease becomes particularly high at
uch levels.
ontrast-enhanced noninvasive coronary angiography.
oninvasive coronary angiography is performed after the
ntravenous administration of iodinated contrast agent, with
lectrocardiogram synchronization and during breath-
olding to minimize motion artifacts. The data are initially
econstructed into two-dimensional axial images with sub-
equent three-dimensional postprocessing. Multiplanar re-
ormat, maximum intensity projection, volume rendering, or
irtual angioscopy can be performed and aid in the diagnosis
f coronary stenosis, as shown in Figure 6.
It appears that the diagnostic accuracy of multidetector-
ow computed tomography is reasonable, but complete
ithin 10 Years Is Derived From the Data on
s According to
eam CT
Probability Within 10 Years
According to Exercise
Electrocardiography
ium Score <80 Abnormal Normal
0.2 4.0 0.4
0.4 8.0 0.9
0.6 12.0 1.3
0.9 15.0 1.9
1.0 19.0 2.3
1.2 22.0 2.8
1.4 25.0 3.3
2.2 33.0 4.8
3.4 44.0 7.4
4.8 52.0 10.0
of the results of electron beam computed tomography (CT)
is increased to 27% if a calcium score is 80, and reduced
eenland P, Gaziano M. N Engl J Med 2003;349:465–73.
cessed computed tomography (CT) coronary angiography (lower row, B)
ges can be adjusted to resemble conventional coronary angiography planes.
 left circumflex; OM  obtuse marginal; PDA  posterior descendingnt W
Year
ron B
Calc
basisstpro
T ima
; LCxein. Reproduced with permission from Fayad ZA, Fuster V, Nikolaou K,
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December 7, 2004:2099–110 Year in Atherothrombosisssessment can be hindered by calcium deposits in the vessel
all and by motion artifacts, particularly in patients with
igh heart rates (35). Recent studies show a sensitivity of
9% to 92% and specificity of 93% to 98%, after the
xclusion of arteries considered of subdiagnostic image
uality (42–44). It is expected that resolution will improve
ith the newer generation 64-slice multidetector-row com-
uted tomography that may offer marked improvement in
iagnostic capability.
Noninvasive angiography may be of relevant clinical
enefit in patients after percutaneous or surgical revascular-
zation. Preliminary studies show good results in detecting
otal occlusions but rather low sensitivity and specificity to
etect in-stent restenosis or saphenous vein graft lesions
45,46).
The use of computed tomography to detect non-calcified
therosclerotic plaques prone to rupture shows preliminary,
romising results (47–50). Nevertheless, when compared
ith intravascular ultrasound, multidetector-row computed
omography underestimates plaque burden, probably due to
ower spatial resolution, especially in distal segments
51,52).
ontrast, non-contrast coronary, and whole-body enhanced
agnetic resonance angiography. Recently, contrast-
nhanced coronary magnetic resonance angiography was
ound to have high specificity and sensitivity compared with
-ray angiography for the detection of luminal narrowing
50% (53,54). Technical advances of faster processing (55)
nd new contrast agents (56) are promising. In addition,
ontrast-enhanced magnetic resonance angiography meth-
dology has been proposed as a technique for the assessment
f coronary anomalies (57), patency of bypass grafts (58),
ost-stent improvement in coronary flow (59), and coronary
n-stent restenosis (60). Thus far, the sensitivity and spec-
ficity are quite reasonable.
igure 7. Relative risks of future cardiovascular events across a full clinical ran
isks; red bars  risks adjusted for Framingham risk score. Adapted with perGlobal coherent-free precession (GCFP) is a new con- cept of MRI (61). In brief, protons in moving blood are
tagged” every few milliseconds as they travel through an
rbitrary region in space. Simultaneous with tagging of new
lood, previously tagged blood is maintained in the GCFP
tate, which allows visualization of pulsating blood flowing
hrough three-dimensional space for distances of up to 16
m. Such non-enhanced contrast technology can be of
ignificant future value by outlining regional anatomy (i.e.,
oronary) and characteristics of flow.
egional high-resolution MRI for plaque characteriza-
ion. Magnetic resonance differentiates plaque components
n the basis of biophysical and biochemical parameters such
s chemical composition, water content, physical state,
olecular motion, or diffusion. Thus far, magnetic reso-
ance plaque characterization of the carotid arteries and
orta has proven to be very sensitive and specific as com-
ared with that of the coronary arteries (62,63). A crucial
ltimate goal of cardiovascular noninvasive imaging is to
ave reliable technology for plaque characterization of the
oronary arteries. Guided by contrast-enhanced computed
omography, high resolution MRI coupled with the previ-
usly mentioned contrast-enhanced molecular magnetic
esonance angiography promise to fulfill this crucial ulti-
ate goal (6,64–66).
ERUM MARKERS FOR HIGH-RISK PATIENTS
RP. During the last year, research in the CRP continued
o provide additional information for the practicing physi-
ian. Two studies and a consensus document require de-
ailed evaluation. The first study evaluated the positive
redictive value of very low (0.5 mg/l) and very high levels
f hsCRP (10.0 mg/l) among 27,939 apparently healthy
omen who were followed up for MI, stroke, coronary
evascularization, or cardiovascular death (67). Cardiovas-
igh sensitivity C-reactive protein (hsCRP) values. Blue bars crude relative
n from Ridker PM. Circulation 2004;109:1955–9.ge of hular risks increased linearly from the very lowest (referent)
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Year in Atherothrombosis December 7, 2004:2099–110o the very highest levels of hsCRP (p for trend 0.001),
ven after adjustment for FRS and after control of diabetes,
s seen in Figure 7. The investigators concluded that both
ery low (0.5 mg/l) and very high (10 mg/l) levels of
sCRP provide important prognostic information on car-
iovascular risk, and that hsCRP is clinically useful for risk
rediction across a full range of values and across a full range
f FRS.
The second study was less positive and generated signif-
cant controversy. Danesh et al. (68) evaluated the odds ratio
or coronary heart disease using baseline measurements
rom the Reykjavik prospective study of 18,569 participants.
fter adjustment for established risk factors, the odds ratio
or coronary artery disease was 1.45 (95% CI, 1.25 to 1.68)
or participants in the highest third of the group with
espect to those in the bottom third. Furthermore, a
eta-analysis involving a total of 7,068 patients with
oronary heart disease was also performed, with similar
esults. The investigators concluded than CRP is a relatively
oderate predictor of coronary heart disease, and, therefore,
ecommendations regarding its use may need revision (68).
The consensus document, a statement for healthcare
rofessionals from the Centers for Disease Control and
revention and the American Heart Association reviewed
he scientific evidence on CRP and developed guidelines for
linical and public health practice. Using the traditional
lass I, IIa, IIb, and III categories, the workshop recom-
ended the following indications for the measurement of
sCRP (69):
Class I: none.
Class IIa: as an independent marker of risk in those
judged as intermediate risk by global risk assessment (10%
to 20% risk of coronary heart disease in 10 years).
Class IIb: as an independent marker for recurrent isch-
emic events (death, MI, and restenosis after percutaneous
coronary intervention) in patients with chronic stable
angina or acute coronary syndromes. The benefit of
therapy based in this strategy remains uncertain. For
laboratory testing, measurement of hsCRP should be
done twice, optimally two weeks apart, fasting or non-
fasting in metabolically stable patients. If hsCRP level is
10 mg/l, the test should be repeated and the patient
examined for sources of infection or inflammation.
Relative risk category and average hsCRP level: low1
mg/l; average: 1.0 to 3.0 mg/; high 3.0 mg/l.
Class III: the adult population should not be screened for
hsCRP for purposes of cardiovascular risk assessment.
Application of secondary prevention measures or manage-
ment guidelines for acute coronary syndromes should not
depend on hsCRP determination.
The document offers additional practical information and
eviews areas in which questions persist with serum markers
or clinical use. This article is a must for the clinician
nterested in using hsCRP for patient risk-stratification and
are. l-type natriuretic peptide. Natriuretic peptides are
ounter-regulatory hormones involved in volume homeosta-
is and cardiovascular remodeling. Nevertheless, the prog-
ostic significance of plasma natriuretic peptide levels in
pparently asymptomatic persons has not been established.
he Framingham Heart study investigators prospectively
tudied 3,346 persons without heart failure and examined
he relations of plasma B-type natriuretic peptide and
-terminal pro-atrial natriuretic peptide (BNP) to the risk
f death from any cause, a first major cardiovascular event,
eart failure, atrial fibrillation, stroke or transient ischemic
ttack, and coronary heart disease (70). During a mean
ollow-up of 5.2 years, 119 participants died, and 79 had a
rst cardiovascular event. After adjustment for cardiovascu-
ar risk factors, each increment of one standard deviation in
og BNP levels was associated with a 27% increase in the
isk of death (p 0.009), a 28% increase in the risk of a first
ardiovascular event (p  0.03), a 77% increase in the risk
f heart failure (p  0.001), a 66% increase in the risk of
trial fibrillation (p  0.001), and a 53% increase in the risk
f stroke or transient ischemic attack (p  0.002). The
nvestigators concluded that plasma BNP levels predict the
isk of death and cardiovascular events after adjustment for
raditional risk factors.
oluble CD40 ligand. Increasing evidence suggests that
D40 ligand plays an important part in disease progression
nd plaque destabilization. The CD40-CD40 ligand system
s widely distributed on a variety of leukocytic and non-
eukocytic cells, including endothelial and smooth-muscle
ells and on activated platelets. CD40 ligand also occurs in
fully active form, termed soluble CD40 ligand (sCD40L),
hich is proinflammatory for endothelial cells and promotes
F expression on monocytes and endothelial cells. More-
ver, sCD40L ligand contains a KGD sequence that is
pecific for the major platelet integrin IIb3 (glycoprotein
Ib/IIIa) necessary for the stability of arterial thrombi (71).
Elevated plasma concentrations of sCD40L indicate in-
reased risk for future cardiovascular events in apparently
ealthy people. Within the last year, three studies evaluating
CD40L required detailed review. The 7E3 Fab Antiplate-
et Therapy in Unstable Refractory Angina (CAPTURE)
tudy group investigated the predictive value of soluble
D40 ligand as a marker for clinical outcome and the
herapeutic effect of glycoprotein IIb/IIIa receptor inhibi-
ion in 1,088 patients with acute coronary syndromes
reviously randomized in a trial comparing abciximab with
lacebo before coronary angioplasty. Additional informa-
ion was obtained from a different cohort of 626 patients
ith acute chest pain (71). Among patients receiving
lacebo, elevated soluble CD40 ligand levels indicated a
ignificantly increased risk of death or nonfatal MI during
ix months of follow-up. The increased risk in patients with
levated soluble CD40 ligand levels was significantly re-
uced by treatment with abciximab, whereas there was no
ignificant treatment effect of abciximab in patients with low
evels of soluble CD40 ligand. These results suggest that
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December 7, 2004:2099–110 Year in Atherothrombosislevation of soluble CD40 ligand identifies a subgroup of
atients at high risk who are likely to benefit from anti-
latelet treatment with abciximab (71).
The Orbofiban in Patients with Unstable Coronary
yndromes-Thrombolysis In Myocardial Infarction-16
OPUS-TIMI-16) group tested the hypothesis that plasma
CD40L, alone or in combination with troponin (cTnI) or
RP, may identify patients with acute coronary syndromes
t heightened risk for recurrent cardiac events (72). Patients
eveloping death, MI, or congestive heart failure had
ignificantly higher sCD40L plasma levels than controls.
fter adjustment for other risk predictors, sCD40L levels
ere associated with higher risk for death/MI/congestive
eart failure. The investigators concluded that elevated
lasma levels of sCD40L identify patients with acute
oronary syndromes at heightened risk of death and recur-
ent MI independent of other predictive variables, including
TnI and CRP.
The third study (73) evaluated the hypothesis that dia-
etic patients have elevated plasma levels of sCD40L and
hat treatment with the insulin-sensitizing thiazolidinedio-
es lowers this index of inflammation. Subjects with type 1
r type 2 diabetes had higher (p  0.001) sCD40L plasma
evels compared with age-matched controls. Regression
nalysis demonstrated a significant (p  0.001) association
etween plasma sCD40L and diabetes, independent of
raditional and novel risk factors for coronary artery disease.
urthermore, administration of troglitazone to type 2 dia-
etics diminished sCD40L plasma levels by 29% (p 
.001), suggesting that the inflammatory state in diabetics
ay be suitable for novel therapy (73).
lasma levels of myeloperoxidase. Myeloperoxidase, a
eukocyte enzyme, is elevated in culprit lesions from patients
ith acute coronary syndromes. The Cleveland Clinic
oundation investigators assessed the value of plasma levels
f myeloperoxidase as a predictor of the risk of cardiovas-
ular events in 604 sequential patients presenting to the
mergency department with chest pain (74). Initial plasma
yeloperoxidase levels predicted the risk of MI, even in
atients who are negative for troponin T (0.1 ng/ml) at
aseline (p 0.001). Myeloperoxidase levels at presentation
lso predicted the risk of major adverse cardiac events (MI,
he need for revascularization, or death) within 30 days and
months after presentation (p  0.001). In patients
ithout evidence of myocardial necrosis (defined as those
ho were negative for troponin T), the baseline myeloper-
xidase levels independently predicted the risk of major
dverse coronary events at 30 days and 6 months follow-up.
irculating tissue factor. Several studies suggest a role for
n increased circulating pool of TF in atherothrombotic
iseases. Sambola et al. (75) evaluated circulating TF
ctivity and blood thrombogenicity in patients with type 2
iabetes mellitus, smokers, and hyperlipidemic subjects.
atients with poor glycemic control showed increased cir-
ulating TF (p  0.0001), and increased blood thrombo-
enicity. Two hours after smoking two cigarettes, TF also dncreased (p  0.003). Hyperlipidemic subjects also showed
igher TF activity (p  0.035) than healthy volunteers.
EW THERAPIES FOR CORONARY ARTERY DISEASE
harmacologic therapy. HDL THERAPIES. A major ad-
ance in the pharmacologic treatment of coronary artery
isease is rapidly evolving by the stimulation of the reverse
ipid transport system to stabilize or even regress coronary
theroma. Two studies published within the last year are
orth mentioning. The first study was a randomized,
ouble-blind, multicenter, parallel-treatment study to assess
he effects of two different doses of intravenous rApo A-I
ilano or placebo administered weekly for five weeks on
oronary atheroma volume as measured by intravascular
ltrasound in patients with acute coronary syndromes (76).
he absolute reduction in atheroma volume in the com-
ined treatment groups was 14.1 mm3 or a 4.2% decrease
rom baseline (p 0.001). The investigators concluded that
ApoA-I Milano produced significant regression of coro-
ary atherosclerosis as measured by intravascular ultrasound.
he authors also called for larger clinical trials with mor-
idity and mortality end points to confirm these results (76).
The second study evaluated the effects of torcetrapib, an
nhibitor of cholesteryl ester transfer protein (CETP). This
lasma glycoprotein facilitates transfer of cholesteryl esters
rom HDL cholesterol to apolipoprotein B-containing li-
oproteins. Humans with CETP deficiency due to molec-
lar defects in the CETP gene have markedly elevated
lasma levels of HDL cholesterol and apolipoprotein A-I,
eading to the concept that CETP inhibition might increase
DL cholesterol levels (77). A single-blind, placebo-
ontrolled study in 19 subjects with low levels of HDL
holesterol (40 mg/dl [1.0 mmol/l]), 9 of whom were also
reated with 20 mg of atorvastatin daily, was performed.
reatment with 120 mg of torcetrapib daily increased
lasma concentrations of HDL cholesterol by 61% in the
torvastatin cohort (p  0.001), and by 46% in the non-
torvastatin cohort (p  0.001). Treatment with 120 mg
wice daily increased HDL cholesterol by 106% (p 
.001). Torcetrapib also reduced LDL cholesterol levels by
7% in the atorvastatin cohort (p  0.02). Finally, torce-
rapib significantly altered the distribution of cholesterol
mong HDL and LDL subclasses, resulting in increases in
he mean particle size of HDL and LDL in each cohort.
he investigators concluded that, in subjects with low HDL
holesterol levels, CETP inhibition with torcetrapib mark-
dly increased HDL cholesterol levels and also decreased
DL cholesterol levels, both when administered as mono-
herapy and when administered in combination with a
tatin.
TATIN THERAPY. Additional relevant information was also
ublished comparing different doses of statins. The first
tudy, Reversal of Atherosclerosis with Aggressive Lipid
owering (REVERSAL) (78), was a double-blind, ran-
omized active control multicenter trial comparing the
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Year in Atherothrombosis December 7, 2004:2099–110ffects of two different statins administered for 18 months.
ntravascular ultrasound was used to measure the progres-
ion of atherosclerosis in 654 patients randomly assigned to
eceive a moderate lipid-lowering regimen consisting of 40
g of pravastatin or an intensive lipid-lowering regimen
onsisting of 80 mg of atorvastatin. Baseline LDL choles-
erol level (mean, 150.2 mg/dl [3.89 mmol/l] in both
reatment groups) was reduced to 110 mg/dl (2.85 mmol/l)
n the pravastatin group and to 79 mg/dl (2.05 mmol/l) in
he atorvastatin group (p  0.001). C-reactive protein
ecreased 5.2% with pravastatin and 36.4% with atorvasta-
in (p  0.001). The primary end point (percentage change
n atheroma volume) showed a significantly lower progres-
ion rate in the atorvastatin (intensive) group (p  0.02).
rogression of coronary atherosclerosis occurred in the
ravastatin group compared with baseline. Progression did
ot occur in the atorvastatin group compared with baseline.
he investigators concluded that, for patients with coronary
eart disease, intensive lipid-lowering treatment with ator-
astatin reduced progression of coronary atherosclerosis
ompared with pravastatin.
The clinical relevance of these observed differences was
legantly addressed by the TIMI-22 investigators who
andomized 4,162 patients with acute coronary syndromes
o 40 mg of pravastatin daily (standard therapy) or 80 mg of
torvastatin daily (intensive therapy) (79). Median LDL
holesterol level achieved during treatment was 95 mg/dl
2.46 mmol/l) in the standard therapy group and 62 mg/dl
1.60 mmol/l) in the high-dose therapy group (p  0.001).
he primary end point, a composite of death from any
ause, MI, documented unstable angina requiring rehospi-
alization, revascularization (performed at least 30 days after
andomization), and stroke was 26.3% in the pravastatin
roup and 22.4% in the atorvastatin group (p  0.005; 95%
I, 5% to 26%). The investigators concluded that, among
atients who have recently had an acute coronary syndrome,
n intensive lipid-lowering statin regimen provides greater
rotection against death or major cardiovascular events than
oes a standard regimen (79).
NTITHROMBOTIC THERAPY. In addition to HDL and
tatin therapy, antithrombotic therapy with the direct
hrombin inhibitor ximelagatran offered additional benefit
n the pharmacologic therapy of patients with coronary
rtery disease (80). In a placebo-controlled, double-blind,
ulticenter, multinational, dose-guiding study involving
,883 patients with acute MI, oral ximelagatran significantly
educed the risk of death, nonfatal MI, and severe recurrent
schemia compared with placebo from 16.3% to 12.7%
hazard ratio 0.76, 95% CI 0.59 to 0.98, p  0.036). The
nvestigators concluded that oral direct thrombin inhibition
ith ximelagatran prevents major cardiovascular events
uring six months of treatment in patients who have had a
ecent MI. However, safety issues are still a major concern.
nterventional therapy. Last year was especially productive
n the interventional approach for patients with coronaryrtery disease. O’Neill and Dixon (81) elegantly summa-
ized these advances in their review article entitled “The
ear in Interventional Cardiology” previously published in
ACC. Two important issues in the treatment of acute MI
ere successfully addressed with randomized trials: 1) in
ospitals without percutaneous transluminal coronary an-
ioplasty capabilities, should we give thrombolysis or refer
he patient for emergent percutaneous transluminal coro-
ary angioplasty? and 2) after successful thrombolysis,
hould we proceed with immediate stenting or continue
ith the recommended, more conservative, watchful wait-
ng approach followed by elective stenting? In addition,
ajor trials in the prevention of restenosis with drug-eluting
tents were also published. The reader is referred to this
rticle for details on these areas (81).
cknowledgments
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